ProfileGDS5678 / 1441319_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 56% 42% 54% 42% 41% 41% 41% 42% 43% 42% 43% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0085442
GSM967853U87-EV human glioblastoma xenograft - Control 23.4092456
GSM967854U87-EV human glioblastoma xenograft - Control 32.9704242
GSM967855U87-EV human glioblastoma xenograft - Control 43.2807654
GSM967856U87-EV human glioblastoma xenograft - Control 52.9192142
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0406941
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9960541
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9441941
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9397842
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9690743
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9626442
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9523743
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9707742
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9706242